Skip to main content
OpenTrials
Completed

NCT Number: NCT04662736

Tedizolid Suppressive Antimicrobial Therapy in a Reference Center

the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone and Joint Infection

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospices Civils de Lyon

Lyon, 69004, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy

Exclusion criteria

-

Treatment and study plan

patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

Other

description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy

Primary outcomes

  1. rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

    Time frame: between 2016 and 2021

    proportion of patients having tedizolid as a suppressive antibiotic therapy

  2. rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic

    Time frame: 2 years

    proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy

  3. rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive

    Time frame: through study completion, an average of 1 year

    proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy

  4. Description of patients having had a BJI/PJI treated with tedizolid as a suppressive

    Time frame: 2 years

    type of patients: age, CMI, comorbidities...

  5. Description of BJI/PJI treated with tedizolid as a suppressive

    Time frame: 2 years

    implant or prothese or not, acute/ chronic, bacteriology

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Tedizolid Suppressive Antimicrobial Therapy

Acronym: TediSAT

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 10, 2020
Registry last updated
Jun 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.